HMP closes deal for MultiMedia Healthcare/Freedom

Share this article:

Malvern, Pa.-based HMP Communications, a privately held medical publishing and communications company, has acquired MultiMedia Healthcare/Freedom, a subsidiary of Freedom Communications Inc.

Financial terms of the transaction were not disclosed.

In a statement, HMP said the acquisition complements its wound care group and "will considerably increase its position in the geriatric marketplace, doubling its size within this market." The combined entity, operating under the name HMP Communications, increases the number of healthcare publications HMP produces to 12.

"This acquisition builds upon HMP's existing publications and services geared toward the aging population and complements HMP's offering across all company divisions," Charles Benaiah, president and chief operating officer of HMP Communications, said in the statement. "As we set out this year to build upon HMP's core capabilities, in MMHC we found a company with synergistic opportunities for growth. Following the acquisition, HMP will have increased its infrastructure and resources to best serve our customer base and our increased size positions HMP as a true leader in healthcare publishing across multiple disciplines."

HMP will acquire MMHC publications Clinical Geriatrics, a peer-reviewed journal focused on issues related to the diagnosis and management of long term care patients, and Annals of Long Term Care, a peer-reviewed medical journal focused on issues related to the treatment and management of the mature patient. In addition, MMHC provides a broad range of consultative communications services to pharmaceutical clients through its Programs in Medicine division, which complements HMPs's MedPro and NACCME divisions. HMP plans to maintain MMHC's Princeton office.

Share this article:
close

Next Article in News

Email Newsletters

More in News

Lilly takes on Amgen's Enbrel

Lilly takes on Amgen's Enbrel

Phase-III tests indicate Lilly's experimental treatment bests Amgen's for moderate-to-severe plaque psoriasis.

Five things for pharma marketers to know: Thursday, August 21

Five things for pharma marketers to know: Thursday, ...

An Ebola survivor is set to leave Emory University Hospital, but the cause of the cure is uncertain, the FDA has approved a new type 1 diabetes test, and the ...

Sanofi expands Gaucher disease portfolio

Sanofi expands Gaucher disease portfolio

The oral medication Cerdelga joins Cerezyme in its Gaucher disease arsenal. Sanofi expects the drug will be priced "on par" with Cerezyme, which goes for around $300,000 a year in ...